Loading...
Market
What will be the total weight loss comparison in a new study of Mounjaro and Ozempic by end of 2024?
2
Resolution / Starting Odds
Mounjaro > 10% more effective • 25%
Mounjaro 5-10% more effective • 25%
Ozempic 5-10% more effective • 25%
Ozempic > 10% more effective • 25%
Published study results and medical journals
Story
JAMA Internal Medicine Study: Mounjaro Leads to Greater Weight Loss Than Ozempic
Jul 8, 2024, 04:00 PM
A new study published in JAMA Internal Medicine has found that Eli Lilly's Mounjaro (tirzepatide) leads to significantly greater weight loss compared to Novo Nordisk's Ozempic (semaglutide). The study, which involved 20,000 participants, used real-world data and matched propensity analysis to compare the effectiveness of the two drugs. Results indicate that patients taking Mounjaro lost more weight than those on Ozempic, and the longer the treatment duration, the wider the gap in weight loss between the two groups. Additionally, tirzepatide, the active ingredient in Mounjaro, also outperformed semaglutide in Wegovy and Zepbound.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%
Above 50% • 25%
30%-50% • 25%
10%-30% • 25%
Below 10% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
Confirms significant risk • 25%
No significant risk found • 25%
Inconclusive results • 25%
Study retracted • 25%
Increased Coverage • 25%
Decreased Coverage • 25%
No Change • 25%
Other Health Risks Highlighted • 25%
No new data released • 25%
Reduction below 20% • 25%
Reduction between 20% and 30% • 25%
Reduction above 30% • 25%
Increased Sales • 25%
Decreased Sales • 25%
No Significant Change • 25%
Product Recall • 25%